|
121
|
323
|
7farA |
Crystal structure of pde5a in complex with inhibitor l12 |
|
123
|
323
|
7faqA |
Crystal structure of pde5a in complex with inhibitor l1 |
|
125
|
316
|
7f0iA |
Phosphodiesterase-9a in complex with inhibitor 4b |
|
122
|
315
|
8bpyA |
X-ray structure of pde9a in complex with inhibitor 13a |
|
126
|
320
|
6lzzA |
Crystal structure of the pde9 catalytic domain in complex with inhibitor 4a |
|
135
|
324
|
6l6eA |
Human pde5 catalytic core in complex with avanafil |
|
143
|
815
|
7jsnB |
Structure of the visual signaling complex between transducin and phosphodiesterase 6 |
|
2
|
87
|
7jsnC |
Structure of the visual signaling complex between transducin and phosphodiesterase 6 |
|
162
|
820
|
7jsnA |
Structure of the visual signaling complex between transducin and phosphodiesterase 6 |
|
107
|
406
|
6x88A |
Pde6 chicken gaf domain |
|
123
|
312
|
7bpiA |
The crystal structue of pde10a complexed with 14 |
|
115
|
325
|
6vbiA |
Crystal structure of pde5 in complex with a non-competitive inhibitor |
|
0
|
4
|
5e8fD |
Structure of fully modified geranylgeranylated pde6c peptide in complex with pde6d |
|
185
|
813
|
6mzbA |
Cryo-em structure of phosphodiesterase 6 |
|
173
|
812
|
6mzbB |
Cryo-em structure of phosphodiesterase 6 |
|
1
|
86
|
6mzbC |
Cryo-em structure of phosphodiesterase 6 |
|
134
|
322
|
6mscA |
Novel, potent, selective and brain penetrant phosphodiesterase 10a inhibitors |
|
130
|
328
|
6msaA |
Novel, potent, selective and brain penetrant phosphodiesterase 10a inhibitors |
|
120
|
323
|
5znlA |
Crystal structure of pde10a catalytic domain complexed with lhb-6 |
|
113
|
324
|
6ijiA |
Crystal structure of pde10 in complex with inhibitor 2b |
|
122
|
322
|
6ijhA |
Crystal structure of pde10 in complex with inhibitor af-399/14387019 |
|
130
|
322
|
6a3nA |
Crystal structure of the pde9 catalytic domain in complex with inhibitor 2 |
|
127
|
324
|
3tggA |
A novel series of potent and selective pde5 inhibitor2 |
|
127
|
324
|
3tgeA |
A novel series of potent and selective pde5 inhibitor1 |
|
125
|
326
|
6acbA |
Crystal structure of pde5 in complex with inhibitor lw1805 |
|
115
|
312
|
5k9rA |
Pde10a with imidazopyrazine inhibitor |
|
130
|
313
|
5i2rA |
Human pde10a in complex with 3-(2-phenylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one |
|
121
|
326
|
5zz2A |
Crystal structure of pde5 in complex with inhibitor lw1634 |
|
121
|
322
|
5xujA |
Crystal structure of pde10a in complex with 7-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]pyrimidine |
|
125
|
322
|
5xuiA |
Crystal structure of pde10a in complex with 2-methyl-5-[2-([1,2,4]triazolo[1,5-a]pyrimidin-2-yl)et hyl]pyrazolo[1,5-a]pyrimidin-7-ol |
|
126
|
307
|
5c29A |
Pde10 complexed with 6-chloro-2-cyclopropyl-5-methyl-n-propyl-pyrimidin-4-amine |
|
126
|
308
|
5c2hA |
Pde10 complexed with 6-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[3-(2-quinolyl)propoxy]pyrimidin-4-amine |
|
127
|
323
|
5c2eA |
Pde10 complexed with6-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[2-(2-pyridyl)ethoxy]pyrimidin-4-amine |
|
136
|
325
|
5c28A |
Pde10 complexed with 6-chloro-2-cyclopropyl-5-methyl-pyrimidin-4-amine |
|
135
|
325
|
5c1wA |
Pde10 complexed with 4,6-dichloro-2-cyclopropyl-5-methyl-pyrimidine |
|
133
|
323
|
5c2aA |
Pde10 complexed with 6-chloro-2-cyclopropyl-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-pyrimidin-4-amine |
|
125
|
315
|
5b4lA |
Crystal structure of the catalytic domain of human pde10a complexed with 1-(cyclopropylmethyl)-5-(2-(2,3-dihydro-1h-imidazo[1,2-a]benzimidazol-1-yl)ethoxy)-3-(1-phenyl-1h-pyrazol-5-yl)pyridazin-4(1h)-one |
|
126
|
322
|
4ys7A |
Co-crystal structure of 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-3-methyl-3h-imidazo[4,5-f]quinoline (compound 39) with pde10a |
|
128
|
321
|
4yqhA |
2-[2-(4-phenyl-1h-imidazol-2-yl)ethyl]quinoxaline (sunovion compound 14) co-crystallized with pde10a |
|
133
|
328
|
4e90A |
Human phosphodiesterase 9 in complex with inhibitors |
|
124
|
307
|
4dffA |
The sar development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10a inhibitors for the treatment of schizophrenia |
|
128
|
318
|
4ddlA |
Pde10a crystal structure complexed with novel inhibitor |
|
124
|
312
|
4bbxA |
Discovery of a potent, selective and orally active pde10a inhibitor for the treatment of schizophrenia |
|
131
|
320
|
4aelA |
Pde10a in complex with the inhibitor az5 |
|
140
|
328
|
4ajfA |
Identification and structural characterization of pde10 fragment inhibitors |
|
133
|
324
|
4ajdA |
Identification and structural characterization of pde10 fragment inhibitors |
|
135
|
320
|
4ajmA |
Development of a plate-based optical biosensor methodology to identify pde10 fragment inhibitors |
|
131
|
321
|
4ajgA |
Identification and structural characterization of pde10 fragment inhibitors |
|
123
|
315
|
3wylA |
Crystal structure of the catalytic domain of pde10a complexed with 5-methoxy-3-(1-phenyl-1h-pyrazol-5-yl)-1-(3-(trifluoromethyl)phenyl)pyridazin-4(1h)-one |
|
125
|
324
|
3wi2A |
Crystal structure of pde10a in complex with inhibitor |
